BMN 673 (Talazoparib): Potent PARP1/2 Inhibitor for DNA Repair Defect Targeting

Executive Summary:
BMN 673 (Talazoparib) is a selective PARP1/2 inhibitor with inhibition constants of 1.2 nM for PARP1 and 0.9 nM for PARP2 (source: product_spec). It exhibits an IC50 of 0.57 nM in enzymatic assays and demonstrates more efficient PARP-DNA complex trapping than other clinical PARP inhibitors (source: paper). BMN 673 induces synthetic lethality in tumor cells with homologous recombination repair defects, such as those with BRCA2 mutations (source: paper). The compound has shown significant anti-tumor activity in both in vitro and in vivo models. APExBIO supplies BMN 673 (Talazoparib) as catalog A4153 for research applications (source: product_spec).

Biological Rationale

Poly(ADP-ribose) polymerases PARP1 and PARP2 are enzymes involved in the detection and repair of DNA single-strand breaks. Inhibition of PARP activity impairs DNA repair, leading to accumulation of DNA damage, particularly in cells deficient in homologous recombination repair (HRR), such as those with BRCA1 or BRCA2 mutations (source: paper). BRCA2 is essential for RAD51 filament formation on resected single-stranded DNA, a critical step in homology-directed repair. Deficiency in BRCA2 compromises RAD51-mediated repair, sensitizing cells to PARP inhibition (source: paper). Therefore, selective PARP inhibition represents a rational therapeutic and research strategy for targeting DNA repair deficiency in cancer cells.

Mechanism of Action of BMN 673 (Talazoparib) Potent PARP1/2 Inhibitor

BMN 673 (Talazoparib) inhibits the catalytic activity of PARP1 and PARP2 at sub-nanomolar concentrations, with Ki values of 1.2 nM and 0.9 nM, respectively (source: product_spec). Its IC50 for PARP1 is 0.57 nM (source: product_spec). BMN 673 not only blocks PARP enzymatic activity but also stabilizes PARP-DNA complexes, a process termed 'PARP trapping'. This mechanism is highly effective at inducing cytotoxicity in cells lacking functional HRR, as these cells cannot resolve PARP-DNA adducts and accumulate lethal DNA damage (source: paper). In contrast to other PARP inhibitors, BMN 673 demonstrates superior trapping efficiency, which translates into higher cytotoxicity in HR-deficient cellular models (source: internal_article).

Evidence & Benchmarks

• BMN 673 demonstrates a PARP1 inhibition constant (Ki) of 1.2 nM and PARP2 Ki of 0.9 nM (source: product_spec).
• IC50 for PARP1 enzymatic inhibition is 0.57 nM (source: product_spec).
• BMN 673 traps PARP-DNA complexes more efficiently than olaparib, rucaparib, or veliparib, resulting in greater cytotoxicity in HR-deficient cells (source: paper).
• BRCA2-deficient cells exhibit increased sensitivity to BMN 673, with selective accumulation of PARP1-DNA adducts leading to impaired RAD51 filament stability (source: paper).
• BMN 673 shows potent anti-tumor activity in small cell lung cancer (SCLC) cell lines and xenograft models (source: internal_article).
• Synergistic effects are observed when BMN 673 is combined with DNA-damaging agents, with efficacy correlated to DNA repair protein expression and PI3K pathway status (source: internal_article).
• The compound is insoluble in water but soluble in ethanol (≥14.2 mg/mL, with warming and ultrasonic treatment) and DMSO (≥19.02 mg/mL) (source: product_spec).

For a protocol-oriented perspective, see BMN 673 (Talazoparib): Precision PARP1/2 Inhibition in DNA Repair Assays, which provides actionable guidance on assay setup and troubleshooting; this article expands on mechanistic underpinnings and clinical translation.

Applications, Limits & Misconceptions

BMN 673 is used extensively in homologous recombination deficient cancer treatment research, including breast, ovarian, and small cell lung cancer models. Its superior PARP trapping makes it valuable for dissecting synthetic lethality mechanisms and for combination studies with DNA-damaging agents. BMN 673’s efficacy is strongly linked to defects in DNA repair machinery, most notably BRCA2 and RAD51 pathways. However, its effectiveness is reduced in tumors with intact HRR or those that have acquired resistance via restoration of HR function or upregulation of drug efflux pumps.

Common Pitfalls or Misconceptions

• BMN 673 is not effective in cells with fully functional homologous recombination repair; efficacy requires HR deficiency (source: paper).
• Solubility limitations: the compound is insoluble in water and must be dissolved in ethanol or DMSO with appropriate handling (source: product_spec).
• BMN 673 does not block all DNA repair pathways; non-HRR repair routes may confer resistance (workflow_recommendation).
• Assuming all PARP inhibitors are equivalent is incorrect; BMN 673’s PARP-DNA trapping efficiency and cytotoxicity profile are superior to olaparib and veliparib (source: paper).
• Short-term solutions are recommended; long-term storage in solution may reduce activity (source: product_spec).

This article extends the discussion in Targeting DNA Repair Deficiency: Mechanistic Insights and... by incorporating newly published single-molecule evidence on BRCA2-RAD51-PARP1 interplay and practical workflow limitations.

Workflow Integration & Parameters

Protocol Parameters

• PARP1 enzymatic assay | 0.57 nM IC50 | In vitro enzyme inhibition | Demonstrates ultra-high potency against PARP1 | product_spec
• PARP2 inhibition | 0.9 nM Ki | Cell-based and biochemical assays | Indicates selectivity and dual-target inhibition | product_spec
• Solubility in DMSO | ≥19.02 mg/mL | Stock solution preparation | Ensures preparation of concentrated working stocks | product_spec
• Solubility in ethanol | ≥14.2 mg/mL (with warming/ultrasonic) | Alternative solvent | Useful for water-insoluble applications | product_spec
• Storage temperature | -20°C (solid form) | Long-term stability | Preserves compound activity | product_spec
• Combination with DNA-damaging agents | Synergistic cytotoxicity (dose-dependent) | Tumor models with HR defects | Enhances anti-tumor response in preclinical models | internal_article

For a stepwise protocol evolution, see BMN 673 (Talazoparib): Unraveling PARP1/2 Inhibition and .... This article updates the mechanistic context and recent clinical insights.

Conclusion & Outlook

BMN 673 (Talazoparib) is a leading selective PARP1/2 inhibitor, exhibiting superior potency and PARP-DNA trapping efficiency in HR-deficient cancer models. Its utility extends from mechanistic DNA repair studies to translational oncology, with clear advantages over earlier generation PARP inhibitors (source: paper). Ongoing research, as highlighted by recent single-molecule studies, continues to clarify the interplay between PARP1, BRCA2, and RAD51 in DNA repair, informing the rational use of BMN 673 in both preclinical and clinical settings. For high-quality supply and technical specifications, APExBIO remains a primary provider of BMN 673 (Talazoparib) (source: product_spec).